Misplaced Pages

Aubrey de Grey

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by 167.196.94.7 (talk) at 17:53, 30 March 2005. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 17:53, 30 March 2005 by 167.196.94.7 (talk)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
File:De grey.jpg
Aubrey de Grey

Aubrey de Grey (b. 1963) is a biogerontologist at the University of Cambridge in England who is currently working to expedite the development of a 'cure' for human aging, a medical goal he refers to as engineered negligible senescence (senescence means aging). To this end, he has identified what he concludes are the seven areas of the aging process that need to be addressed medically before this can be done. De Grey is also an outspoken supporter of life extension. He has been interviewed in recent years in many news sources, including the BBC, the New York Times, Fortune Magazine, and Popular Science.

Prior to his work as a biologist, de Grey was formally trained in computer science and bioinformatics. He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today, and that the science is actually ahead of the funding. He works to identify and promote specific technological approaches to the reversal of various aspects of aging and for the more proactive and urgent approaches to extending the healthy human lifespan.

As of 2005, de Grey's current work at Cambridge centered around a detailed plan called Strategies for Engineered Negligible Senescence (SENS) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the Methuselah Mouse Prize, a contest designed to accelerate research into effective life extension interventions by awarding prizes to researchers who extend the lifespan of mice to unprecedented lengths. The prize reached $1 million USD in March 2005. De Grey believes that once this objective has been achieved in mice, a large amount of funding will be diverted to this kind of research, which would accelerate progress.

External links

Category: